ofloxacin (floxin) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Ofloxacin is one of a new generation of fluorinated quinolones structurally related to nalidixic acid, primary mechanism of action is inhibition of bacterial DNA gyrase. It is an orally administered broad spectrum antibacterial drug active against most Gram-negative bacteria, many Gram-positive bacteria and some anaerobes. Clinical trials to date have demonstrated the efficacy of ofloxacin in the treatment of lower respiratory tract infections, urinary tract infections, and sexually transmitted diseases. Adverse effects to ofloxacin are usually mild and include gastrointestinal, central nervous system, and hypersensitivity reactions. Also available in solution for treatment of otic and ophthalmic bacterial infections.   NCATS

Chemistry

  • SMILES: CC1COC2=C(N3CCN(C)CC3)C(F)=CC4=C2N1C=C(C(O)=O)C4=O
  • InChIKey: GSDSWSVVBLHKDQ-UHFFFAOYSA-N
  • Mol. Mass: 361.3675
  • ALogP: 1.54
  • ChEMBL Molecule:
    ofloxacin  
More Chemistry

Pharmacology

Drug Pricing (per unit)

United States

$1.8050 - $23.2740

Australia

$7.9081
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

8-fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6h-1-oxa-3a-aza-phenalene-5-carboxylic acid | dl-8280 | exocin | floxin | floxin otic | gailuoxian | hoe-280 | ocuflox | ofloxacin | (-)-ofloxacin | ofloxacine | ofloxacin hcl | ofloxacin hydrochloride | ofloxacino | ofloxacin s-(-)-form | ofloxacinum | oflx | ovax | oxaldin | prifloxcin | prifloxin | (s)-ofloxacin | tarivid | tarivid 400 | tarivid i.v. | visiren

Organizations (65)

Research & Development (42)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (23)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (34)

Approved Indications (8)


 

Acne Vulgaris

Bacterial Infections (approved 2006)

Bronchitis, Chronic

Conjunctivitis, Bacterial (approved 2013)

Corneal Ulcer (approved 2013)

Infections

Otitis (approved 2007)

Otitis Externa

Experimental Indications - Clinical Trial Phases 1-4 (29)


 

Adenocarcinoma (Phase 1/Phase 2)

Amoxicillin (Phase 4)

Bacterial Infections (Phase 1)

Cataract (Phase 4)

Conjunctivitis (Phase 2)

Conjunctivitis, Bacterial (Phase 3)

Corneal Transplantation (Phase 4)

Diabetic Foot (Phase 3)

Dry Eye Syndromes (Phase 4)

Fever (Phase 4)

Glaucoma (Phase 3)

Glaucoma, Open-Angle (Phase 3)

Hearing Loss (Phase 1)

HIV Infections (Phase 4)

Infections (Phase 4)

Keratitis (Phase 3)

Macular Degeneration (Phase 1)

Metronidazole (Phase 4)

Multiple Myeloma (Phase 3)

Ocular Hypertension (Phase 3)

Ofloxacin (Phase 4)

Osteomyelitis (Phase 3)

Otitis Media (Phase 4)

Pelvic Inflammatory Disease (Phase 4)

Periodontitis (Phase 4)

Root Planing (Phase 4)

Short Bowel Syndrome (Phase 1)

Urinary Tract Infections (Phase 4)

Uterine Diseases (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 33
  • # of Trial Organizations: 42

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue